Creathor joins Series C round of Sinopsys Surgical
(PresseBox) - ulder, Colorado, USA, 18.03.2015 - Creathor has invested into Sinopsys Surgical, a clinical stage medical device company in Boulder, Colorado. Sinopsys has developed a stent device called the Sinopsys Lacrimal Stent. The lead indication for the stent is chronic rhinosinusitis with additional use in epiphora and potential in allergic rhinitis.
Participants in this Series C round beside Creathor are strategic, institutional and private investors. All of the company's existing investors took part in the financing.
"The company is very grateful for the strong support from both its existing and new investors.", comments Harry Ross, CEO of Sinopsys, "We are eager to begin our next phase of U.S. trials in an exciting range of applications." he adds.
"The Sinopsys Lacrimal Stent has the potential to help millions of patients suffering from chronic rhinosinusitis, an indication with high medical need and limited therapeutic options", says Christian Leikert, Investment Manager at Creathor "We are looking forward to working with Sinopsys in this exiting environment."
The funds will be used to further develop the Sinopsys Lacrimal Stent in clinical trials and to prepare the regulatory filings as well as the market launch of the device.
Creathor manages funds of more than EUR 180m and invests in technology-oriented companies and entrepreneurs in the mobile, social e-commerce, e-commerce, media, cloud, cleantech, life science and medtech industry. The management team of Creathor Venture consists of the CEO Dr. Gert Köhler, Cédric Köhler and Karlheinz Schmelig. The team has been investing successfully in the early-stage venture capital business for over 30 years. During that time, more than 200 technology companies have been funded, more than 20 international IPOs conducted and many companies were successfully sold. Creathor has achieved exceptional fund returns in the past.
Creathor Venture as a pan European Venture capital company holds offices in Bad Homburg, in Tutzing (near Munich), in Zurich and in Stockholm and supports a portfolio of over 30 innovative companies as lead-investor.
The investors of the current fund include the European Union, through which the fund receives funding from the "Competitiveness and Innovation Framework Programme" (CIP), and the "ERP EIF fund of funds" and the LfA - Gesellschaft für Vermögensverwaltung mbH, both facilities of the European Investment Fund ("EIF"), fund of funds, family offices and entrepreneurs. As the largest investor in Creathor (over EUR 50m) the management underlines its entrepreneurial orientation.
Creathor manages funds of more than EUR 180m and invests in technology-oriented companies and entrepreneurs in the mobile, social e-commerce, e-commerce, media, cloud, cleantech, life science and medtech industry. The management team of Creathor Venture consists of the CEO Dr. Gert Köhler, Cédric Köhler and Karlheinz Schmelig. The team has been investing successfully in the early-stage venture capital business for over 30 years. During that time, more than 200 technology companies have been funded, more than 20 international IPOs conducted and many companies were successfully sold. Creathor has achieved exceptional fund returns in the past.
Creathor Venture as a pan European Venture capital company holds offices in Bad Homburg, in Tutzing (near Munich), in Zurich and in Stockholm and supports a portfolio of over 30 innovative companies as lead-investor.
The investors of the current fund include the European Union, through which the fund receives funding from the "Competitiveness and Innovation Framework Programme" (CIP), and the "ERP EIF fund of funds" and the LfA - Gesellschaft für Vermögensverwaltung mbH, both facilities of the European Investment Fund ("EIF"), fund of funds, family offices and entrepreneurs. As the largest investor in Creathor (over EUR 50m) the management underlines its entrepreneurial orientation.
Datum: 18.03.2015 - 14:45 Uhr
Sprache: Deutsch
News-ID 379454
Anzahl Zeichen: 2734
contact information:
Town:
Bad Homburg
Kategorie:
Diese Pressemitteilung wurde bisher 330 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Creathor joins Series C round of Sinopsys Surgical"
steht unter der journalistisch-redaktionellen Verantwortung von
Creathor Venture Management GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
